Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech.
The retrospective, monocentric study carried out in the Ophthalmology Department at Brest University Hospital, evaluates the efficacy and tolerance of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT), our patented photo-biomodulation technology, in the treatment of meibomian gland dysfunction (MGD).
We’re proud to announce our Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech.
The randomized, controlled, blinded study evaluates the efficacy of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT) in the treatment of meibomian gland dysfunction (MGD) and evaporative dry eye (EDE) compared to a control group.